Literature DB >> 26016594

Correlation between tea consumption and prevalence of hypertension among Singaporean Chinese residents aged ⩾40 years.

W Li1,2, J Yang3, X S Zhu4, S C Li5, P C Ho6.   

Abstract

By a cross-sectional epidemiology study, we attempted to correlate the consumption of tea and/or health supplements, living habits and socio-demographic factors to the prevalence of hypertension among Singaporean Chinese residents. Singaporean Chinese residents aged ⩾40 years were randomly selected and interviewed face-to-face by clinical research assistants. Hypertension was defined as measured systolic blood pressure at least 140 mm Hg and/or diastolic blood pressure at least 90  mmHg or self-reported history/treatment for hypertension. The prevalence of hypertension among the whole investigated population (N=1184, 58.27% females) was 49.73% and the prevalence increased to 66.47% in the sub-population aged ⩾60 years. High risk of hypertension was associated with age ⩾60 years (odds ratio (OR): 4.15-4.19, P<0.01), obesity (body mass index >25 kg m(-2), OR: 2.10-2.11, P<0.01), family history of hypertension (OR: 2.69-2.76, P<0.01), diabetes history (OR: 2.29-2.33, P<0.01), hyperlipidemia history (OR: 1.79-1.80, P<0.01), male (OR: 1.56-1.59, P<0.01) and coffee intake (OR: 1.44-1.46, P<0.05). In contrast, drinking green tea at least 150 ml per week was associated with lower hypertension risk (OR: 0.63, 95% confidence interval (CI): 0.43-0.91, P<0.05). Drinking combination of green tea and British tea was associated with higher reduction in the risk of hypertension (OR: 0.58, 95% CI: 0.39-0.85, P<0.05). This cross-sectional study suggests that consumption of tea, especially green tea and British tea, was associated with lowering the risk of hypertension. On the other hand, consumption of coffee could be a risk factor of hypertension. These findings may provide useful information for health promotion to reduce risk of hypertension and warrant further study to confirm and elucidate such association.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26016594     DOI: 10.1038/jhh.2015.45

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  30 in total

1.  A randomized, double-blind, placebo-controlled study to evaluate the efficacy and tolerability of Fufang Danshen (Salvia miltiorrhiza) as add-on antihypertensive therapy in Taiwanese patients with uncontrolled hypertension.

Authors:  Tsung-Yuan Yang; James Cheng-Chung Wei; Ming-Yung Lee; C M Balance Chen; Kwo-Chang Ueng
Journal:  Phytother Res       Date:  2011-09-02       Impact factor: 5.878

Review 2.  Habitual coffee consumption and risk of hypertension: a systematic review and meta-analysis of prospective observational studies.

Authors:  Zhenzhen Zhang; Gang Hu; Benjamin Caballero; Lawrence Appel; Liwei Chen
Journal:  Am J Clin Nutr       Date:  2011-03-30       Impact factor: 7.045

3.  Modulatory effect of green tea extract on hepatic key enzymes of glucose metabolism in streptozotocin and high fat diet induced diabetic rats.

Authors:  Ramalingam Sundaram; Rajendran Naresh; Palanivelu Shanthi; Panchanatham Sachdanandam
Journal:  Phytomedicine       Date:  2013-02-28       Impact factor: 5.340

4.  Beneficial effects of catechin-rich green tea and inulin on the body composition of overweight adults.

Authors:  Hsin-Yi Yang; Suh-Ching Yang; Jane C-J Chao; Jiun-Rong Chen
Journal:  Br J Nutr       Date:  2011-10-28       Impact factor: 3.718

5.  Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score.

Authors:  Gregory Y H Lip; Lars Frison; Jonathan L Halperin; Deirdre A Lane
Journal:  J Am Coll Cardiol       Date:  2010-11-24       Impact factor: 24.094

6.  Panax notoginseng and its components decreased hypertension via stimulation of endothelial-dependent vessel dilatation.

Authors:  Chunshui Pan; Yingqing Huo; Xiaojin An; Gurbakhshish Singh; Meng Chen; Zhaoxiang Yang; Junxue Pu; Jian Li
Journal:  Vascul Pharmacol       Date:  2012-01-03       Impact factor: 5.773

Review 7.  The role of tea and tea flavonoids in cardiovascular health.

Authors:  Verena Stangl; Mario Lorenz; Karl Stangl
Journal:  Mol Nutr Food Res       Date:  2006-02       Impact factor: 5.914

Review 8.  Tea and health: studies in humans.

Authors:  Naghma Khan; Hasan Mukhtar
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

9.  Folic acid supplementation during early pregnancy and the risk of gestational hypertension and preeclampsia.

Authors:  Zhiwen Li; Rongwei Ye; Le Zhang; Hongtian Li; Jianmeng Liu; Aiguo Ren
Journal:  Hypertension       Date:  2013-02-11       Impact factor: 10.190

Review 10.  How to calculate sample size for different study designs in medical research?

Authors:  Jaykaran Charan; Tamoghna Biswas
Journal:  Indian J Psychol Med       Date:  2013-04
View more
  4 in total

1.  Blood Pressure Is Associated with Tea Consumption: A Cross-sectional Study in a Rural, Elderly Population of Jiangsu China.

Authors:  J-Y Yin; S-Y Duan; F-C Liu; Q-K Yao; S Tu; Y Xu; C-W Pan
Journal:  J Nutr Health Aging       Date:  2017       Impact factor: 4.075

2.  Association between tea consumption and risk of cognitive disorders: A dose-response meta-analysis of observational studies.

Authors:  Xueying Liu; Xiaoyuan Du; Guanying Han; Wenyuan Gao
Journal:  Oncotarget       Date:  2017-06-27

3.  Health-related quality of life of middle-aged and elderly people with hypertension: A cross-sectional survey from a rural area in China.

Authors:  Qi Chen; Li Ran; Mengying Li; Xiaodong Tan
Journal:  PLoS One       Date:  2021-02-02       Impact factor: 3.240

4.  Dietary patterns associated hyperuricemia among Chinese aged 45 to 59 years: An observational study.

Authors:  Fang He; Lei-Lei Wang; Xiao-Long Yu
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.